5241642026-04-012026-06-305241642026-06-305241642026-04-012026-06-30in-capmkt:OtherExpenses1Member5241642026-04-012026-06-30in-capmkt:ReportableSegments1Member5241642026-04-012026-06-30in-capmkt:ReportableSegments2Member5241642026-04-012026-06-30in-capmkt:ReportableSegments3Member5241642026-04-012026-06-30in-capmkt:ReportableSegments1Member5241642026-04-012026-06-30in-capmkt:ReportableSegments2Member5241642026-04-012026-06-30in-capmkt:ReportableSegments3Member5241642026-04-012026-06-30in-capmkt:ReportableSegments1Member5241642026-06-30in-capmkt:ReportableSegments1Member5241642026-04-012026-06-30in-capmkt:ReportableSegments2Member5241642026-06-30in-capmkt:ReportableSegments2Member5241642026-04-012026-06-30in-capmkt:ReportableSegments3Member5241642026-06-30in-capmkt:ReportableSegments3Member5241642026-04-012026-06-30in-capmkt:ReportableSegments1Member5241642026-06-30in-capmkt:ReportableSegments1Member5241642026-04-012026-06-30in-capmkt:ReportableSegments2Member5241642026-06-30in-capmkt:ReportableSegments2Member5241642026-04-012026-06-30in-capmkt:ReportableSegments3Member5241642026-06-30in-capmkt:ReportableSegments3Member5241642026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15241642026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss15241642026-04-012026-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524164IOLCPNOTLISTEDINE485C01029IOL Chemicals and Pharmaceuticals LimitedMain BoardEquity2026-04-012027-03-312026-08-102026-08-03INRCroresQuarterlyFirst quarterMulti segment2026-08-1012:30:002026-08-1014:05:00Declaration of unmodified opinionfalsefalseNo default on loans during the quarter ended June 30 2026. Further, the Company has not issued any debt securities.2026-04-012026-06-30UnauditedStandalone756260000081800000764440000050676000007500000-29530000071210000036400000213200000103520000067767000008677000000867700000217300000560000022290000006448000000000644800000-1030000063450000058710000022.22.2002.22.2NOTES: <br /> <br /> 1. The above unaudited financial results for the quarter ended 30th June 2026 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their meetings held on 10th August 2026. These results have been subjected to limited review by Statutory Auditors who have expressed an unmodified opinion on these results. <br /> <br /> 2. The financial results are prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and are in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements} Regulations, 2015. <br /> <br /> 3. The figures for the quarter ended 31st March 2026, are the balancing figures between the audited figures for the full financial and the unaudited published figures up to 9 months ended 31st December 2025, which were subjected to limited review by the statutory auditors. <br /> <br /> 4. As per Ind-AS 108 - Operating Segments, the Company has two reportable Operating Segments namely ‘Pharmaceuticals’ and ‘Chemicals’. The financial information for these segments has been provided in Financial Results. <br /> <br /> 5. The previous financial period figures have been regrouped/rearranged/restated, wherever considered necessary. <br /> <br /> by order of the Board <br /> IOL Chemicals and Pharmaceuticals Limited <br /> <br /> <br /> Varinder Gupta <br /> Managing Director <br /> DIN: 00044068 <br /> <br /> Place: Ludhiana <br /> Date: 10th August 2026 Other Expenses1035200000Pharmaceutical4694900000Chemical3649600000Unallocated8180000084263000007819000007644400000Pharmaceutical688100000Chemical173200000Unallocated086130000036400000-42800000867700000Pharmaceutical16648800000Chemical6947600000Unallocated465500000028251400000028251400000Pharmaceutical2835800000Chemical3305700000Unallocated3491600000963310000009633100000NOTES: <br /> <br /> 1. The above unaudited financial results for the quarter ended 30th June 2026 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their meetings held on 10th August 2026. These results have been subjected to limited review by Statutory Auditors who have expressed an unmodified opinion on these results. <br /> <br /> 2. The financial results are prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and are in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements} Regulations, 2015. <br /> <br /> 3. The figures for the quarter ended 31st March 2026, are the balancing figures between the audited figures for the full financial and the unaudited published figures up to 9 months ended 31st December 2025, which were subjected to limited review by the statutory auditors. <br /> <br /> 4. As per Ind-AS 108 - Operating Segments, the Company has two reportable Operating Segments namely ‘Pharmaceuticals’ and ‘Chemicals’. The financial information for these segments has been provided in Financial Results. <br /> <br /> 5. The previous financial period figures have been regrouped/rearranged/restated, wherever considered necessary. <br /> <br /> by order of the Board <br /> IOL Chemicals and Pharmaceuticals Limited <br /> <br /> <br /> Varinder Gupta <br /> Managing Director <br /> DIN: 00044068 <br /> <br /> Place: Ludhiana <br /> Date: 10th August 2026 <br /> <br /> Items that will not be reclassified to profit or loss-13500000-13500000-3400000Items that will be reclassified to profit or loss-300000-300000-100000-10300000UnauditedtrueM/s. Ashwani & Associates, Chartered Accountantstrue2029-01-31